Cargando…

Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)

BACKGROUND: The increasing incidence and poor outcome associated with MPM requires finding effective treatment for this disease. PD1/PD-L1 pathway plays a central role in tumor immune evasion and appears to be predictive and prognostic marker. PD-L1 is expressed in many different human cancers but i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cedrés, Susana, Ponce-Aix, Santiago, Zugazagoitia, Jon, Sansano, Irene, Enguita, Ana, Navarro-Mendivil, Alejandro, Martinez-Marti, Alex, Martinez, Pablo, Felip, Enriqueta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361537/ https://www.ncbi.nlm.nih.gov/pubmed/25774992 http://dx.doi.org/10.1371/journal.pone.0121071

Ejemplares similares

Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients
por: Cedres, Susana, et al.
Publicado: (2023)

MA04.07 Clinical Characteristics and Outcomes in Patients With Malignant Pleural Mesothelioma (MPM) with COVID-19 Infection
por: Cedres, S., et al.
Publicado: (2021)

Malignant Pleural Mesothelioma (MPM) Presenting as Hydropneumothorax
por: Kuramochi, Masami, et al.
Publicado: (2023)

KAP1 is a new non-genetic vulnerability of malignant pleural mesothelioma (MPM)
por: Lorenzini, Eugenia, et al.
Publicado: (2022)

Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort
por: Cedres, Susana, et al.
Publicado: (2021)

Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment
por: Gounant, Valérie, et al.
Publicado: (2021)

Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)
por: Klampatsa, Astero, et al.
Publicado: (2017)

Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study
por: Pagano, Maria, et al.
Publicado: (2020)

Long Non Coding RNAs (lncRNAs) Are Dysregulated in Malignant Pleural Mesothelioma (MPM)
por: Wright, Casey M., et al.
Publicado: (2013)

ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment
por: Ponce, Santiago, et al.
Publicado: (2023)

The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM)
por: Yuen, Man Lee, et al.
Publicado: (2021)

Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM)
por: Lapidot, Moshe, et al.
Publicado: (2021)

Genomic and Transcriptomic Analyses of Malignant Pleural Mesothelioma (MPM) Samples Reveal Crucial Insights for Preclinical Testing
por: Laure, Alexander, et al.
Publicado: (2023)

Genomic Deletion of BAP1 and CDKN2A Are Useful Markers for Quality Control of Malignant Pleural Mesothelioma (MPM) Primary Cultures
por: Sarun, Kadir Harun, et al.
Publicado: (2018)

A deep learning-based model (DeepMPM) to help predict survival in patients with malignant pleural mesothelioma
por: Li, Wei, et al.
Publicado: (2023)

Detection of Circulating Tumor Cells (CTCs) in Malignant Pleural Mesothelioma (MPM) with the “Universal” CTC-Chip and An Anti-Podoplanin Antibody NZ-1.2
por: Kuwata, Taiji, et al.
Publicado: (2020)

Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM)
por: Mendoza, Tito R., et al.
Publicado: (2019)

The Use of Immunohistochemistry, Fluorescence in situ Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review
por: Rozitis, Eric, et al.
Publicado: (2020)

Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation
por: Cedrés, Susana, et al.
Publicado: (2018)

In Silico and In Vitro Analyses of LncRNAs as Potential Regulators in the Transition from the Epithelioid to Sarcomatoid Histotype of Malignant Pleural Mesothelioma (MPM)
por: Singh, Anand S., et al.
Publicado: (2018)

Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM)
por: Lapidot, Moshe, et al.
Publicado: (2020)

Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study
por: Brcic, Luka, et al.
Publicado: (2021)

Anti-mesothelin vaccine CRS-207 with or without low-dose cyclophosphamide plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM)
por: Hassan, Raffit, et al.
Publicado: (2015)

Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study
por: Mark, M., et al.
Publicado: (2022)

Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma
por: Watanabe, Takuya, et al.
Publicado: (2018)

Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD‐L1
por: Tsubouchi, Kazuya, et al.
Publicado: (2020)

The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study
por: Zauderer, Marjorie G, et al.
Publicado: (2021)

SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020)
por: Nadal, E., et al.
Publicado: (2021)

Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion
por: Tsuji, S, et al.
Publicado: (2010)

PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study
por: Jin, Liu, et al.
Publicado: (2020)

MTA1 promotes metastasis of MPM via suppression of E-cadherin
por: Xu, Caihua, et al.
Publicado: (2015)

PI3K Pathway in NSCLC
por: Martinez-Martí, Alex, et al.
Publicado: (2012)

Interrelations between Patients’ Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients
por: Callejo, Ana, et al.
Publicado: (2021)

Molecular profiling of long‐term responders to immune checkpoint inhibitors in advanced non‐small cell lung cancer
por: Frigola, Joan, et al.
Publicado: (2021)

Malignant pleural mesothelioma: an update
por: Hajj, Glaucia N. M., et al.
Publicado: (2021)

Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients
por: Martinez, Pablo, et al.
Publicado: (2013)

Prognostic and predictive role of [(18)F]fluorodeoxyglucose positron emission tomography (FDG‐PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up‐front pemetrexed‐based chemotherapy
por: Zucali, Paolo Andrea, et al.
Publicado: (2017)

Digital quantitative assessment of PD-L1 using digital spatial profiling
por: Gupta, Swati, et al.
Publicado: (2020)

Higher concordance of PD‐L1 expression between biopsies and effusions in epithelioid than in nonepithelioid pleural mesothelioma
por: Mansour, Mohammed S. I., et al.
Publicado: (2021)

Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti–PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma
por: Danlos, François-Xavier, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0n9n1g0kafc34s5cg9o1sqnq12